Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 2

2(40.0%)

Phase 3

1(20.0%)

5Total

Phase 1(2)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05163717Phase 2Terminated

INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD

Role: lead

NCT03557333Phase 3Completed

Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)

Role: lead

NCT03541356Phase 2Completed

Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal

Role: lead

NCT03401346Phase 1Completed

Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

Role: lead

NCT03624322Phase 1Completed

Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101

Role: lead

All 5 trials loaded